Jérémie Meyer, Author at BaseLaunch

Features

Looking for biopharma professionals with experience in areas such as R&D/commercial/BD&L to support emerging biotech companies

Starting a biotech and developing drugs needs world class science as a foundation. But equally important is to back up the (usually) academic inventors of…

Jérémie Meyer23.09.2019

Interviews

Interview with Alex Mayweg, partner at Versant Ventures and president of Ridgeline, a Versant Ventures Discovery Engine

“We make no compromises in creating the highest potential company” Versant Ventures has a strong history in building successful companies such as Therachon, Black Diamond…

Jérémie Meyer30.07.2019

Interviews

Podcast Recap: Interview with George Yancopoulos, President and CSO of Regeneron Pharmaceuticals – “an overnight success story that took 25 years”

Regeneron Pharmaceuticals is one of the biggest biotech success stories. It’s the first biotech in history with 6 marketed drugs, all originated from its own…

Jérémie Meyer30.07.2019

Portfolio news

T3 Pharmaceuticals wins W.A. de Vigier Award

T3 Pharmaceuticals is among the winners of this year’s W.A. de Vigier Award. The spin-off from the University of Basel is developing a targeted cancer…

Jérémie Meyer28.05.2019

Interviews

UCSF’s interview with Rob Nelson of ARCH Venture Partners

ARCH Venture Partners is behind companies such as Illumina, Alnylam, Unity Biotechnology, Receptos, Agios Pharmaceuticals, Grail, Bluebird, and many more. This interview is part of…

Jérémie Meyer24.05.2019

Sifted top healthtech accelerator in Europe

Features

BaseLaunch is top European accelerator

Healthcare Accelerator BaseLaunch, which is operated by the location promotion organization BaselArea.swiss, is among the leading accelerators of its kind in Europe, according to a…

Jérémie Meyer22.05.2019

Features

Our fully equipped lab space significantly reduces the cost to start a biotech

Launching a biotech is a daunting endeavor. Resources – both human and capital - are scarce and have to be fully dedicated to advancing science…

Jérémie Meyer29.04.2019

Features

Event Impressions and some Key Quotes: Perfecting Partnerships for Life Sciences Startup Success

Closing a deal is more art than science. This is especially true in the biopharma industry where investments and partnerships are key elements to success.…

Jérémie Meyer02.04.2019

Portfolio news

Polyneuron raises CHF 22.5 Million in Series A to advance novel Therapies for Autoimmune Diseases

Leading venture capital firm Sofinnova Partners led the Series A financing, together with New Enterprise Associates, which co-led the round Basel, Switzerland, 28 March 2019–Polyneuron…

Jérémie Meyer28.03.2019

Features

Roche takes Switzerland to number one for patents

In 2018, no other country in Europe saw more patents filed relative to population size than Switzerland. This has been found by a new report…

Jérémie Meyer12.03.2019

Jérémie Meyer

Looking for biopharma professionals with experience in areas such as R&D/commercial/BD&L to support emerging biotech companies

Interview with Alex Mayweg, partner at Versant Ventures and president of Ridgeline, a Versant Ventures Discovery Engine

Podcast Recap: Interview with George Yancopoulos, President and CSO of Regeneron Pharmaceuticals – “an overnight success story that took 25 years”

T3 Pharmaceuticals wins W.A. de Vigier Award

UCSF’s interview with Rob Nelson of ARCH Venture Partners

BaseLaunch is top European accelerator

Our fully equipped lab space significantly reduces the cost to start a biotech

Event Impressions and some Key Quotes: Perfecting Partnerships for Life Sciences Startup Success

Polyneuron raises CHF 22.5 Million in Series A to advance novel Therapies for Autoimmune Diseases

Roche takes Switzerland to number one for patents

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us